2015 Fiscal Year Final Research Report
The development of novel immunotherapy for oral cancer, and identify of biomarker for determine the clinical effect
Project/Area Number |
25463113
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Surgical dentistry
|
Research Institution | Kumamoto University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
篠原 正徳 熊本大学, 医学部附属病院, 非常勤診療医師 (90117127)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Keywords | トランスレーショナルリサーチ / 頭頸部癌 / 扁平上皮癌 / ペプチドワクチン療法 |
Outline of Final Research Achievements |
Our cancer vaccine therapy was well tolerated. The OS of the A24(+) vaccinated group (n = 37) was statistically significantly longer than that of the A24(-) group (n = 18) and median survival time (MST) was 4.9 versus 3.5 months, respectively; P < 0.05. One of the patients exhibited a complete response. In the A24(+) vaccinated group, the ELISPOT assay identified LY6K-, CDCA1-, and IMP3-specific CTL responses in 85.7%, 64.3%, and 42.9% of the patients, respectively. The patients showing LY6K- and CDCA1-specific CTL responses demonstrated a longer OS than those without CTL induction. Moreover, the patients exhibiting CTL induction for multiple peptides demonstrated better clinical responses. The immune response induced by this vaccine may improve the prognosis of patients with advanced HNSCC.
|
Free Research Field |
歯科口腔外科
|